VYNE Therapeutics Inc./$VYNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Ticker
$VYNE
Sector
Primary listing
Employees
10
Headquarters
Website
VYNE Metrics
BasicAdvanced
$21m
-
-$0.62
2.03
-
Price and volume
Market cap
$21m
Beta
2.03
52-week high
$1.96
52-week low
$0.28
Average daily volume
135k
Financial strength
Current ratio
12.53
Quick ratio
12.112
Profitability
EBITDA (TTM)
-29.726
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-4,646.14%
Operating margin (TTM)
-5,219.12%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-38.31%
Return on equity (TTM)
-66.96%
Valuation
Price to revenue (TTM)
47.775
Price to book
0.76
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-0.822
Free cash flow yield (TTM)
-121.64%
Free cash flow per share (TTM)
-0.775
Growth
Revenue change (TTM)
13.77%
Earnings per share change (TTM)
-33.79%
3-year revenue growth (CAGR)
6.12%
10-year revenue growth (CAGR)
-3.91%
3-year earnings per share growth (CAGR)
-56.03%
10-year earnings per share growth (CAGR)
-34.43%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for VYNE Therapeutics Inc. stock?
VYNE Therapeutics Inc. (VYNE) has a market cap of $21M as of May 01, 2026.
What is the P/E ratio for VYNE Therapeutics Inc. stock?
The price to earnings (P/E) ratio for VYNE Therapeutics Inc. (VYNE) stock is 0 as of May 01, 2026.
Does VYNE Therapeutics Inc. stock pay dividends?
No, VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next VYNE Therapeutics Inc. dividend payment date?
VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders.
What is the beta indicator for VYNE Therapeutics Inc.?
VYNE Therapeutics Inc. (VYNE) has a beta rating of 2.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.